AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Immutep to Present New Data from AIPAC-003 Phase II at 2025 San Antonio Breast Cancer Symposium
ByAinvest
Tuesday, Dec 2, 2025 8:03 am ET1min read
Immutep has announced new data from its AIPAC-003 Phase II trial, showing that an immunotherapy-chemotherapy combination of eftilagimod alfa and paclitaxel resulted in strong objective response rates and immune activation in heavily pretreated metastatic breast cancer patients. The trial has also met FDA's Project Optimus requirements and selected 30 mg as the optimal biological dose for eftilagimod alfa. The results will be presented at the 2025 San Antonio Breast Cancer Symposium.
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet